 TRICCAR, Inc. (OTC: FOSI), a bioceutical development and marketing firm, announced that it has completed an agreement for an investment of $18,594,692 via private placement in the public entity from Antonomastic Investment Holdings, Ltd., resulting in the sale of 11,621,683 shares of common stock at $1.60 per share. As part of the investment, Nairobi, Kenya based Antonomastic Investment Holdings, Ltd. will appoint an as yet to be determined member to TRICCAR's board of directors.

TRICCAR, Inc. is a Las Vegas, Nevada-based biomedical company, creating bioceutical solutions that support the health of those suffering from the world's most common illnesses and conditions, including, obesity, hypothyroidism, calcium deficiency, pain, diabetic neuropathy, and trigeminal neuralgia. The Company competes in markets estimated at $1 trillion in annual sales for human and animal formulations. TRICCAR products have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease.

TRICCAR Announces $18.5 Million Private Placement Investment

TRICCAR Announces $18.5 Million Private Placement Investment

Company Info